Faron Pharmaceuticals

Cheers, We’ve recently released an Initiation of Coverage Report on Faron Pharmaceuticals. Faron is a clinical stage drug development company focused on immunology. The lead candidate bexmarilimab is an immuno oncology drug developed for various solid tumors and blood cancers. The full report is availabe to all readers freely. Feel free to ask any questions you may have on the investment case and please remember to tag my name to avoid missing your question. -Antti, Analyst, Life Sciences Inderes - Award Winning Research Risky investment with huge potential Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk ...

Hello Antti! Thank you very much for your response and also for the excellent analyses! Without you, interpreting a company like this would be very difficult for me alone. The industry is so challenging for an ordinary investor like myself. You’re doing a great job, and I appreciate it!

Hi Börsen, Although a bit old, the video and our Initiation of Coverage report are mostly still relevant. The main developments since recording the vid have been the faster than expected development of the phase I/II BEXMAB trial investigating bexmarilimab for treatment of blood cancers. On the other hand, development of the other two bexmarilimab trials MATINS (bex monotherapy in solid tumors) and BEXCOMBO (bex combined with PD-1 inhibitors) have been a bit slower than we anticipated probably due to lack of funding. We commneted on biotech funding recently here. We will be updating our extensive report by the end of the year and provide regular updates on the stock in the mean time. The latest one is Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation

Det här är en över ett halvår gammal video om företaget, men den är ändå bra att titta på om man är intresserad av företaget. Antti är verkligen en utmärkt analytiker. Faron Pharmaceuticals is a drug development company. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. Analyst Antti Siltanen elaborates. 00:00 Antti, what do Faron do in very simple terms? 02:50 The drug candidates 05:30 The biggest risks and uncertainties? 08:50 It’s very probable Faron goes bankrupt and investors loose their money, but on the other hand if a miracle happens the pay off is huge. Why do have an accumulate recommendation to the stock?